NavigAID RA: Patient stratification for rheumatoid arthritis (RA)
NavigAID RA is a patient stratification tool that measures autoantibodies in serum to help group patients based on the immunological processes underlying their condition, to help advance the development of precision medicine treatments and approaches.
RA is a chronic inflammatory autoimmune disease thought to affect up to 1% of the world’s population. This debilitating condition manifests as the breakdown of cartilage and bone, which is underpinned by various autoimmune processes including the formation of autoantibodies (for example against citrullinated peptides) that have emerged as important diagnostic and prognostic markers.
Despite the success and widespread availability of treatments such as TNFα inhibitors, challenges including limited response rates and patient heterogeneity remain, calling for the development of precision medicine treatments and approaches. To achieve this, it is crucial to find ways of effectively stratifying RA patients into disease subgroups, and Protagen has developed its NavigAID biomarker panel—NavigAID RA—in order to do just this.
The NavigAID RA patient stratification tool aims to group patients based on the immunological processes underlying their specific condition, to help advance the development of precision treatments for RA and increase the chances of treatment success.
To find out more about how NavigAID RA is supporting the development of effective treatments, contact us today.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.